Lonza GroupFRA:LO3 -0.07%72 FCF Yield % is -0.58 as of Jun. 28, 2026. GuruFocus rates FRA:LO3 with a GF Score™ of 72/100 and a GF Value™ of €642.72 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Lonza Group ranks better than 51.87% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Lonza Group's FCF Yield % or its related term are showing as below:
FRA:LO3'
s FCF Yield % Range Over the Past 10 Years
Min: -3.64 Med: 0.32 Max: 5.6
Current: -0.58
During the past 13 years, the highest FCF Yield % of Lonza Group was 5.60%. The lowest was -3.64%. And the median was 0.32%.
FRA:LO3's FCF Yield % is ranked better than 51.87% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.455
vs FRA:LO3: -0.58
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Lonza Group FCF Yield % Related Terms
Lonza Group FCF Yield % Historical Data
* Premium members only.
The historical data trend for Lonza Group's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Lonza Group's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lonza Group FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lonza Group's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Lonza Group's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lonza Group (FRA:LO3) has a FCF Yield % of -0.58 as of Jun. 28, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Lonza Group and its competitors. According to the industry distribution chart, Lonza Group ranks #103 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 48.1%.
Is Lonza Group's FCF Yield % too high?
Lonza Group's current FCF Yield % is -0.58. Based on the distribution chart, Lonza Group ranks #103 out of 214 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Lonza Group has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lonza Group's FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lonza Group ranks #103 out of 214 companies for FCF Yield %. This puts Lonza Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Lonza Group and its competitors. Lonza Group's current FCF Yield % is -0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lonza Group stock overvalued right now?
Based on GuruFocus' analysis, Lonza Group (FRA:LO3) is currently considered Modestly Undervalued. The stock's GF Value™ is €642.72, compared to a current price of €579.60 — trading 9.8% below its estimated fair value. The current FCF Yield % is -0.58. Lonza Group's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Lonza Group (FRA:LO3), the current FCF Yield % is -0.58 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lonza Group (FRA:LO3) Overvalued in 2026?
Based on GuruFocus' analysis, Lonza Group stock appears to be undervalued.
The current stock price of €579.60 is trading 9.8% below its estimated GF Value™ of €642.72.
GuruFocus considers Lonza Group to be Modestly Undervalued.
Key valuation signals for FRA:LO3:
FCF Yield %: -0.58
GF Value™: €642.72 vs. price of €579.60 (9.8% below fair value)
No single metric tells the full story. See the FRA:LO3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
72GF Score
Get the complete analysis for FRA:LO3
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LO3 has been successfully added to your 
